학술논문
Characterization of real-world neovascular age-related macular degeneration (nAMD) switch patients treated with brolucizumab (BROL) alternating with other anti-Vascular Endothelial Growth Factors (VEGF) versus brolucizumab alone
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15525783